Argeris N Karabelas sold $136k of RGNX
director at REGENXBIO Inc.. 10,100 shares at an average of $13.51, traded Aug 1, 2024, filed Aug 5, 2024.
Score components
- +15RoleDirector
- +11Trade size$136k at market
- +10Share of holdings soldSold 47% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -9.8%, 3m -30.0%, 6m -37.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001562180-24-006015, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 1, 2024 | MOption exercise Common Stock10b5-1 | +10,000 | $3.76 | $38k | 21,286 | Aug 5, 2024 |
| Aug 1, 2024 | MOption exercise Common Stock10b5-1 | +100 | $12.74 | $1,274 | 21,386 | Aug 5, 2024 |
| Aug 1, 2024 | SOpen-market sale Common Stock10b5-1 | -9,600 | $13.45 | $129k | 11,786 | Aug 5, 2024 |
| Aug 1, 2024 | SOpen-market sale Common Stock10b5-1 | -400 | $14.59 | $5,834 | 11,386 | Aug 5, 2024 |
| Aug 1, 2024 | SOpen-market sale Common Stock10b5-1 | -100 | $15.00 | $1,500 | 11,286 | Aug 5, 2024 |
| Aug 1, 2024 | MOption exercise Stock Options (Right to Buy)derivative10b5-1 | -100 | $0.00 | $0 | 1,400 | Aug 5, 2024 |
| Aug 1, 2024 | MOption exercise Stock Options (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 20,000 | Aug 5, 2024 |
Related signals
Other insiders at REGENXBIO Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 57Moderate | RGNXbuy REGENXBIO Inc. | Gregory Austin Ciongoli director | $949k 102,603 shares | +665% | |
| 0Weak | REGENXBIO Inc. | Steve Pakola Chief Medical Officer | $29k 2,161 shares | -1% | |
| 6Weak | REGENXBIO Inc. | Steve Pakola Chief Medical Officer | $689k 56,333 shares | -24% | |
| 6Weak | REGENXBIO Inc. | Steve Pakola Chief Medical Officer | $169k 15,309 shares | -6% | |
| 2Weak | REGENXBIO Inc. | Steve Pakola Chief Medical Officer | $53k 5,124 shares | -2% | |
| 18Weak | REGENXBIO Inc. | Curran Simpson Chief Executive Officer | $263k 20,811 shares | -9% | |
| 13Weak | REGENXBIO Inc. | Curran Simpson Chief Executive Officer | $76k 7,624 shares | -3% | |
| 13Weak | REGENXBIO Inc. | Curran Simpson Chief Executive Officer | $77k 7,734 shares | -3% | |
| 0Weak | REGENXBIO Inc. | Kenneth T. Mills President and CEO | $163k 20,602 shares | -4% | |
| 0Weak | REGENXBIO Inc. | Argeris N Karabelas director | $101k 10,000 shares | -47% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.